SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are widely used for the treatment of type 2 diabetes, heart failure and chronic kidney disease due to their proven cardiovascular and renal benefits.